Liver cell dysplasia: a premalignant condition

P. P. ANTHONY, C. L. VOGEL, AND L. F. BARKER

From The Bland-Sutton Institute of Pathology, The Middlesex Hospital Medical School, London, The Solid Tumour Centre, Uganda Cancer Institute, Kampala, Uganda, and the Division of Virology, Bureau of Biologics, Food and Drug Administration of the US Public Health Service, Rockville, Maryland, USA

SYNOPSIS Liver cell dysplasia is defined as cellular enlargement, nuclear pleomorphism, and multinucleation of liver cells occurring in groups or occupying whole cirrhotic nodules. The prevalence, natural history, and relationship to the Australia or hepatitis-associated antigen (HAA) have been studied in 552 Ugandan African patients with normal, cirrhotic, and cancerous livers. Liver cell dysplasia was found in only two of 200 (1%) patients with normal livers, in three of 43 (6.9%) of patients with normal livers bearing primary liver cell carcinoma, 35 of 175 (20.3%) patients with cirrhosis, and 80 of 124 (64.5%) of patients with cirrhosis and primary liver cell carcinoma. Cirrhotic patients without dysplasia were, on average, ten years younger than those with dysplasia and the latter were on average six years younger than those with cirrhosis and carcinoma. Liver cell dysplasia occurred more frequently in males than in females. It was found in all but one instance in macro nodular or mixed forms of cirrhosis only. There was a strong relationship between dysplasia and the presence of HAA in 104 patients that suggests a possible carcinogenic mechanism for the long incubation (serum or B) hepatitis virus in liver cell carcinoma. It is concluded that the presence of liver cell dysplasia identifies a group of patients with a high risk of liver cell carcinoma and that they should be followed up by serial alpha-fetoprotein estimations.

Gross morphological abnormality of liver cells in cirrhosis has been noted from time to time (Edmondson and Steiner, 1954; Steiner and Davies, 1957; Higginson and Steiner, 1961), particularly in the macro nodular (posthepatitic or postnecrotic) types (Scheuer, 1968). The terms 'liver cell atypia', 'hyperplastic nodule', and 'regeneration' have been applied to this change. Steiner and Davies (1957) commented on its relative frequency in African, as compared with American cirrhotic livers. The distinction between an atypical nodule and well differentiated liver cell carcinoma may be difficult (Higginson and Steiner, 1961). However, these foci of cellular atypia have not been thought to represent a premalignant or malignant change, the arguments against this being that the histopathological features were different from carcinomas arising in the same livers (Steiner and Davies, 1957) or that such foci could persist in cirrhotic livers for years without carcinoma supervening (Scheuer, 1968). In experimental pathology similar changes may be produced by a variety of means and their interpretation remains uncertain (Butler, 1971).

The considerable disagreement about the true nature of this phenomenon is reflected in the variety of names applied to it. We have chosen 'liver cell dysplasia' as the most appropriate term to describe the histological appearances and the least presumptive as to their nature.

In the course of our continuing studies of primary liver cancer in Uganda we have noted an association of liver cell dysplasia with macro nodular types of cirrhosis and carcinoma of liver cell, but not of bile duct, origin (Anthony, 1972), and we have also found a highly significant association with the presence of the Australia or hepatitis-associated antigen (HAA) (Anthony, Vogel, Sadikali, Barker, and Peterson, 1972). We now report the results of an extended study of its morphology, prevalence, and natural history in normal, cirrhotic, and cancerous livers.

Definition of Liver Cell Dysplasia

Minor inflammatory and regenerative changes are a common finding in livers of African patients suffering from a variety of diseases and have been frequently
Fig. 1  Slight nuclear variability, binucleation, and Kupffer cell hyperplasia in the liver of a Ugandan patient suffering from malnutrition, Salmonella garoli diarrhoea, and pneumococcal pneumonia. In addition, fatty change is also present (haematoxylin-eosin × 300).

Fig. 2  Liver cell dysplasia showing nuclear and cytoplasmic enlargement with gross nuclear pleomorphism and multinucleation. Nucleoli are prominent. Note that this photomicrograph was taken at the same magnification as fig 1 (haematoxylin-eosin × 300).

Fig. 3  A well defined group of dysplastic liver cells (top) in a cirrhotic nodule (haematoxylin-eosin × 100).
Liver cell dysplasia: a premalignant condition

Fig 4  *An entire cirrhotic nodule showing liver cell dysplasia (haematoxylin-eosin × 50).*

commented upon (Hutt, 1971). As illustrated in fig 1 these consist of slight nuclear variability, the presence of occasional double nuclei, and an increase in the number of Kupffer cells. In addition, portal tract inflammation and fibrosis are often present. It is reasonable to assume that these represent a response to the many toxic and infective agents of a tropical environment. Such changes are so common that they call for no special comment in the reporting of routine clinical liver biopsy material in Uganda.

These non-specific reactive changes must be clearly distinguished from liver cell dysplasia which is defined by the following criteria as illustrated in figures 2 to 5.

Cellular enlargement, nuclear pleomorphism with hyperchromasia, and multinucleation are invariably present and are the main identifying features of the lesion. Enlargement is both nuclear and cytoplasmic and is generally two to threefold. The nuclear-cytoplasmic ratio remains normal. Intranuclear inclusions may be seen and nucleoli are prominent.

Cytoplasmic staining is normal though occasionally more glycogen or less is present than in surrounding non-dysplastic liver. Intracytoplasmic bile droplets are occasionally seen in the absence of any evidence of bile duct obstruction. The liver cell plates may be irregular but retain their reticulin framework and normal arrangement of sinusoids.

These changes, when present, are multiple throughout the liver and occur in groups of liver cells or affect a whole cirrhotic nodule.

The appearances are sufficiently striking to be easily observed under low magnification.

**Material and Methods**

The presence or absence of liver cell dysplasia was assessed in histological material from 695 livers of Ugandan African patients admitted to the wards of New Mulago Hospital and the Solid Tumour Centre, Uganda Cancer Institute, Makerere University, Kampala. This comprised 207 necropsies carried out on all patients who died with cirrhosis.
and primary carcinoma of the liver in the years 1964 to 1968 (retrospective series) and 288 patients who were diagnosed to have these two diseases in all necropsies, laparotomies, and needle biopsies in the period May 1969 to April 1972 (prospective series). To this material were added necropsy sections of normal livers from 200 patients who had died from a wide variety of diseases, including tumours metastatic to the liver, taken at random during the period May 1969 to October 1971.

No selection was applied other than availability of sufficient histological material for assessment. In the retrospective and prospective series of patients with cirrhosis and primary carcinoma of the liver material was judged insufficient in 143 cases and these were rejected. The total of 552 cases left for study comprised 200 normal livers as above, 15 normal livers with primary bile duct (cholangiocellular) carcinoma, 43 normal livers with primary liver cell (hepatocellular) carcinoma, 170 cases of cirrhosis, and 124 cases of cirrhosis and liver cell carcinoma. The overall prevalence of liver cell dysplasia, its age and sex distribution, relationship to the presence and type of cirrhosis and primary liver carcinoma were determined in all cases. Standard paraffin sections were stained with haematoxylin and eosin supplemented by Gordon and Sweet’s reticulin, the periodic acid-Schiff reaction before and after diastase, and Lendrum’s martius-scarlet-blue method as necessary.

The presence of HAA was tested for in 125 cases by complement fixation (Shulman and Barker, 1969) and counterelectrophoresis (Gocke and Howe, 1970). Alpha-fetoprotein (AFP) was assayed in 134 cases by immunodiffusion (Abelev, 1968).

Data were statistically analysed using the chi square test.

Results

Prevalence

Table I shows that liver cell dysplasia may occasionally occur in patients suffering from a variety of diseases, including cancer of other organs with or without liver metastases. One of the two patients with dysplasia in this group of 200 died of miliary tuberculosis, the other had an amoebic abscess of the liver which had been clinically misdiagnosed as carcinoma of the liver and treated with large doses of methotrexate. Liver cell dysplasia was not seen in association with 15 bile duct carcinomas all of which developed in normal, ie, non-cirrhotic, livers. Dysplasia was present, however, in three of 43 (6.9\%) liver cell carcinomas arising in non-cirrhotic livers. In all only five of 120 cases of liver cell dysplasia were seen in these three groups comprising 258 patients and these are excluded from further analysis. Nearly all cases of dysplasia (115 of 120) were seen in the 294 cirrhotic patients. The difference in the prevalence of dysplasia between normal and cirrhotic livers is obvious ($\chi^2 = 111.64$; $p$ less than 0.0001). Amongst cirrhotic patients dysplasia was present in 35 of 170 (20.3\%) of those with cirrhosis alone and in 80 of 124 (64.5\%) of those with cirrhosis and liver cell carcinoma, a difference that was also statistically highly significant ($\chi^2 = 58.10$; $p$ less than 0.001).

Age

The mean age of 294 cirrhotic patients with or without liver cell dysplasia is shown in table II which is grouped into those with cirrhosis only and those with cirrhosis and liver cell carcinoma. Though there was a fairly wide scatter around the mean in all groups it does appear that those with cirrhosis who showed no dysplasia were, on average, 10 years younger than those who did. They, in turn, were some six years younger than those with cirrhosis and liver cell carcinoma. In this latter group there was no longer a detectable age difference between those with and those without dysplasia.

Table II  Mean ages of 280 patients with cirrhosis (with or without associated liver cell carcinoma) and liver cell dysplasia

<table>
<thead>
<tr>
<th></th>
<th>No.</th>
<th>Mean Age (yr) (± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cirrhosis only</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Without dysplasia</td>
<td>125</td>
<td>25.4 (± 14.6)</td>
</tr>
<tr>
<td>With dysplasia</td>
<td>34</td>
<td>35.5 (± 15.1)</td>
</tr>
<tr>
<td>Cirrhosis and liver cell carcinoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Without dysplasia</td>
<td>43</td>
<td>41.2 (± 14.6)</td>
</tr>
<tr>
<td>With dysplasia</td>
<td>78</td>
<td>41.2 (± 13.1)</td>
</tr>
</tbody>
</table>

Table I  Liver cell dysplasia in 552 normal, cirrhotic, and cancerous livers

<table>
<thead>
<tr>
<th></th>
<th>No.</th>
<th>Dysplasia (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal livers1</td>
<td>200</td>
<td>2 (1)</td>
</tr>
<tr>
<td>Normal livers with primary bile duct carcinoma</td>
<td>15</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Normal livers with primary liver cell carcinoma</td>
<td>43</td>
<td>3 (6.9)</td>
</tr>
<tr>
<td>Cirrhotic livers</td>
<td>170</td>
<td>35 (20.3)</td>
</tr>
<tr>
<td>Cirrhotic livers with primary liver cell carcinoma</td>
<td>124</td>
<td>80 (64.5)</td>
</tr>
</tbody>
</table>

1 Indicates absence of cirrhosis or primary liver carcinoma but includes metastatic tumours.

Sex

The male to female ratio for the whole group of 294 cirrhotic patients was 3.7 to 1, the male preponderance being more marked for those with cirrhosis and liver cell carcinoma (5.2 to 1) than those with
Liver cell dysplasia: a premalignant condition

cirrhosis alone (3 to 1). It may be seen from the figures shown in table III that 98 of 232 (42·2\%) males showed dysplasia compared with 17 of 62 (27·4\%) females ($\chi^2 = 4·51$; $p$ less than 0·05). Most of this difference was observed amongst those with cirrhosis alone: 31 of 128 (24·2\%) males had dysplasia compared with four of 42 (9·5\%) females. Dysplasia was present in an equal proportion of both sexes amongst those with cirrhosis and liver cell carcinoma: in 67 of 104 (64·4\%) males and 13 of 20 (65\%) females.

### Table III  Sex distribution of liver cell dysplasia in 294 cirrhotic patients with and without liver cell carcinoma

<table>
<thead>
<tr>
<th></th>
<th>No.</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cirrhosis only</td>
<td>170</td>
<td>128</td>
<td>42</td>
</tr>
<tr>
<td>Without dysplasia</td>
<td>135</td>
<td>97</td>
<td>38</td>
</tr>
<tr>
<td>With dysplasia</td>
<td>35</td>
<td>31</td>
<td>4</td>
</tr>
<tr>
<td>Cirrhosis and liver cell carcinoma</td>
<td>124</td>
<td>104</td>
<td>20</td>
</tr>
<tr>
<td>Without dysplasia</td>
<td>44</td>
<td>37</td>
<td>7</td>
</tr>
<tr>
<td>With dysplasia</td>
<td>80</td>
<td>67</td>
<td>13</td>
</tr>
</tbody>
</table>

### Type of Cirrhosis

The criteria used for distinguishing the various types of cirrhosis were those in general use as reviewed by Scheuer (1968). Table IV shows that only one of 29 patients with nutritional (fatty, micronodular) cirrhosis had dysplasia compared with 114 of 265 patients with other types of cirrhosis ($\chi^2 = 17·21$; $p$ less than 0·001). The highest proportions were found in the macronodular (posthepatitic and postnecrotic) types. In all types of cirrhosis dysplasia was seen more frequently in the presence of liver cell carcinoma, the actual proportion being similar to the overall figures presented in table I, an approximately three-fold increase. There were only eight of 124 cases of liver cell carcinoma associated with micronodular cirrhosis.

### Table IV  Liver cell dysplasia and type of cirrhosis (Gall's classification) in 294 patients

<table>
<thead>
<tr>
<th>Type of Cirrhosis</th>
<th>No.</th>
<th>Dysplasia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nutritional</td>
<td>29</td>
<td>1 (3·4%)</td>
</tr>
<tr>
<td>Posthepatitic</td>
<td>140</td>
<td>65 (46·4%)</td>
</tr>
<tr>
<td>Postnecrotic</td>
<td>44</td>
<td>23 (52·2%)</td>
</tr>
<tr>
<td>Mixed</td>
<td>81</td>
<td>26 (32·0%)</td>
</tr>
</tbody>
</table>

### Hepatitis-associated antigen

Hepatitis-associated antigen was tested for in 104 cirrhotics with or without liver cell carcinoma and was found to be present in 41 (39·4\%). Table V presents the details of the relationship between HAA, dysplasia, and cirrhosis with or without associated liver cell carcinoma. It may be seen that there was a difference in the prevalence of HAA between those with dysplasia (31 of 43 or 72\%) and those without (10 of 61 or 16·3\%) that was statistically highly significant ($\chi^2 = 32·77$; $p$ less than 0·0001). The strength of the association between HAA and dysplasia was the same in cirrhotics with and without liver cell carcinoma.

### Table V  Association between HAA and liver cell dysplasia in 104 cirrhotic patients with or without liver cell carcinoma

<table>
<thead>
<tr>
<th></th>
<th>No.</th>
<th>HAA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dysplasia present</td>
<td>43</td>
<td>31 (72·0%)</td>
</tr>
<tr>
<td>Cirrhosis only</td>
<td>14</td>
<td>9 (64·2%)</td>
</tr>
<tr>
<td>Cirrhosis and liver cell carcinoma</td>
<td>29</td>
<td>22 (75·8%)</td>
</tr>
<tr>
<td>Dysplasia absent</td>
<td>61</td>
<td>10 (16·3%)</td>
</tr>
<tr>
<td>Cirrhosis only</td>
<td>46</td>
<td>7 (15·2%)</td>
</tr>
<tr>
<td>Cirrhosis and liver cell carcinoma</td>
<td>15</td>
<td>3 (20·0%)</td>
</tr>
</tbody>
</table>

### Alpha-fetoprotein

Alpha-fetoprotein was tested for in 60 cirrhotics of whom 14 had dysplasia and all were negative. It was also tested for in 45 cirrhotics with liver cell carcinoma of whom 32 (71·1\%) were positive. There was no difference between those with and without dysplasia.

### Discussion

The results of this study suggest that liver cell dysplasia, as defined above, is a premalignant change. This rests on the following arguments.

Liver cell dysplasia is seen only occasionally in people suffering from a variety of diseases, including bile duct carcinoma and malignant tumours metastatic to the liver. It is present in a small proportion of normal livers bearing liver cell carcinoma. It is seen in approximately one-fifth of patients with cirrhosis and two-thirds of cirrhotics with liver cell carcinoma. This increase in prevalence from normal to cirrhosis and carcinoma is a statistically significant one.

Cirrhotic patients without dysplasia are, on average, 10 years younger than those with dysplasia and cirrhotics with dysplasia are, again on average, some six years younger than those with cirrhosis and carcinoma. This suggests that with time there is a progression of cirrhosis to dysplasia and, ultimately, to liver cell carcinoma. These age differences may be regarded as analogous to dysplasia, carcinoma in situ, and invasive carcinoma of the uterine cervix and other sites.

Dysplasia occurs significantly more frequently in males than in females, the differences being greatest amongst those with cirrhosis alone. In Uganda as elsewhere in Africa, there is a marked preponderance of males over females in liver cell carcinoma (Doll, Payne, and Waterhouse, 1966) and males with
cirrhosis may have a higher chance of developing carcinoma than females (Shaper, 1970). Both of these findings are further supported in this study.

Dysplasia is found almost exclusively in macronodular (posthepatic and postnecrotic) types of cirrhosis and very rarely in the micronodular (nutritional, fatty) type. It is a well established fact that liver cell carcinoma arises most frequently in the grossly scarred, macronodular types of cirrhosis (Gall, 1960; Lee, 1966). This was also found to be so in this study.

Available evidence suggests that there may be a geographical variability in the occurrence of liver cell dysplasia in that it appears to be less common in North America (Steiner and Davies, 1957) and in Europe (Scheuer, 1968). This lower incidence would parallel the lower incidence of liver cell carcinoma in these areas (Doll et al, 1966).

Liver cell dysplasia itself is not a malignant change, though its gross nuclear abnormalities, multifocal origin, and nodular pattern may cause difficulty in distinguishing it from nodules of liver cell carcinoma (Higginson and Steiner, 1961). The main distinguishing features of dysplasia from carcinoma are the following:

- Dysplastic liver cells show cytoplasmic as well as nuclear enlargement and, unlike liver cell carcinoma, the nuclear/cytoplasmic ratio remains within normal limits.
- Cytoplasmic staining and granularity are usually normal in dysplasia whereas in liver cell carcinoma there is often some cytoplasmic basophilia.
- In dysplastic nodules the reticulin pattern is usually normal or slightly increased whereas in carcinomatous nodules the reticulin is deficient or lost altogether.
- Most importantly, this study has shown that the AFP test is negative in cirrhosis with dysplasia. If dysplasia itself was a malignant change a proportion of cases should be positive. Over 70% of liver cell carcinomas were AFP positive in this series.

The data presented in this study clarify the uncertainty expressed previously about the relationship between dysplasia and carcinoma. Steiner and Davies (1957) argued that as the morphological appearances of 'liver cell atypia' were different from liver cell carcinoma arising in the same liver, there was no relationship between them. There is, in fact, no reason why there should be a morphological similarity. Scheuer (1968) noted that atypical cellular changes could persist for years without carcinoma developing. This is compatible with the natural history of the lesion as described above and of dysplasia and carcinoma in situ at other sites.

The precise nature of liver cell dysplasia remains uncertain. It is premalignant only in the sense that its presence is associated with an increased risk of liver cell carcinoma. It is of interest that it shows a strong association with the presence of HAA. We have shown previously that in Uganda there exists an approximately 10-fold increase in the prevalence of HAA in cirrhosis (Maynard, Sadikali, Anthony, and Barker, 1970) and liver cell carcinoma (Vogel, Anthony, Sadikali, and Barker, 1970) as compared with the general hospital population. We have also noted that liver cell dysplasia had a statistically significant association with the presence of HAA in both groups of patients (Anthony et al 1972). The data in this study are an extension of the earlier observations in a larger number of patients and are fully supportive. They suggest that dysplasia may indeed be causally related to HAA and chronic infection with the long-incubation (serum or B) hepatitis virus. The relative rarity of dysplastic changes in cirrhosis in the temperate zones (Steiner and Davies, 1957; Higginson and Steiner, 1961; Scheuer, 1968) would, on the other hand, parallel the low prevalence of HAA in these areas (Prince, 1971).

Failure to find the typical virus-core-like particles in the nuclei of liver cells from 17 cases of liver cell carcinoma in this material (O’Conor, Tralka, Henson, and Vogel, 1972) is in contrast with the frequent finding of these particles in the hepatocytes of chronically infected, immunosuppressed patients (Huang, 1971) and asymptomatic HAA carriers (Caramia, De Bac, and Ricci, 1972). This suggests a discordance between HAA production and virus synthesis in some patients with chronic virus B infection.

The work of Harris and his coworkers on cell fusion and malignancy may be relevant in this context (Harris, Miller, Klein, Worst, and Tachibana, 1969). They showed that the malignant potential of cells from three types of tumours, one of which has been induced by polyoma virus, could be suppressed when fused with certain non-malignant cells. The hybrids resulting from such fusions produced segregants in which a loss of chromosomes was associated with reversion to malignant behaviour after a variable period of time. It may be speculated that HAA induces malignant change in liver cells which then fuse with normal liver cells in their vicinity to form large, abnormal, dysplastic cells. Malignancy is thereby suppressed. In some, this may be permanent; in others, the hybrid gradually escapes through loss of chromosomal material and malignant behaviour is then resumed. Much of the circumstantial evidence in this study supports this hypothesis. Ultimately, it is hoped that liver culture systems will be developed to test the effect of HAA-positive human material. Numerous examples of chromosomal abnormalities in cells
Liver cell dysplasia: a premalignant condition

infected with a wide variety of oncogenic and non-oncogenic viruses have already been described (Aula, Nichols, and Levan, 1968).

For practical purposes it may be suggested that the presence of liver cell dysplasia in a patient, particularly in the presence of cirrhosis, must be regarded as evidence of an increased risk of liver cell carcinoma. Such patients should be followed up by serial testing for alpha-fetoprotein. It is hoped that early detection of malignancy in this high risk group may lead to better results of surgical treatment for a tumour of which the prognosis is at present almost hopeless.

We wish to acknowledge the help given by Professors M. S. R. Hutt, R. A. B. Drury, and Dr R. Owor of the Department of Pathology, Makerere University, Kampala, where part of this work was carried out during the tenure of a senior lectureship by one of us (P. P. A.) in 1969/70 and thank them for providing histological material for study thereafter.

References


Liver cell dysplasia: a premalignant condition

P. P. Anthony, C. L. Vogel and L. F. Barker

doi: 10.1136/jcp.26.3.217

Updated information and services can be found at:
http://jcp.bmj.com/content/26/3/217

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/